Catherine A. Sohn - Jan 30, 2025 Form 3 Insider Report for Maze Therapeutics, Inc. (MAZE)

Role
Director
Signature
/s/ Courtney Phillips, as attorney-in-fact
Stock symbol
MAZE
Transactions as of
Jan 30, 2025
Transactions value $
$0
Form type
3
Date filed
1/30/2025, 04:37 PM
Previous filing
Sep 30, 2024
Next filing
Feb 7, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MAZE Stock Option (Right to Buy) Jan 30, 2025 Common Stock 20.7K $10.42 Direct F1
holding MAZE Stock Option (Right to Buy) Jan 30, 2025 Common Stock 5.7K $10.42 Direct F2
holding MAZE Stock Option (Right to Buy) Jan 30, 2025 Common Stock 9.09K $10.42 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 2, 2024.
F2 The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F3 The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.